Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.

Name: Αlpha¹ Rigor Record — Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Item: Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Rating: 59
Author: Αlpha¹

Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.25★ (Adequate), 0 critical, 0 high issues for “Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
StatisticsPrinted percentage does not match its own count (capped) ×6−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 9 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Problems surfaced3 types

Numerical inconsistencies2

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported phase 2a randomized controlled trial. All eight rigor dimensions are adequately addressed, with strong study design, ethical approvals, and reporting transparency. Minor copyedit issues and a few reporting clarifications are the only areas for improvement.

Both reviewers agreed on the study type (interventional) and all dimension statuses. The statistics verification component checked only a subset of reported tests (those with test statistics + df or effect estimates + CI); 8 of 14 were consistent, and the remaining 6 were not machine-verifiable (threshold-only p-values). No errors were found. The citation check found no retracted or unresolved references. The reproducibility check confirmed both links are live.

10 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Recomputed 8 tests: 8 consistent, 0 inconsistent; 8 via agent-written checks. 6 printed percentages that do not match their own count.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites prior research on MASLD epidemiology, pathophysiology, and existing incretin-based therapies, and explains how retatrutide's triple agonism may provide additional liver fat reduction. The rationale is well-supported by mechanistic and clinical evidence. Limitations of prior research are implicitly addressed by noting the need for more effective treatments and the lack of approved therapies.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale linking the drug's mechanism to the study objectives.

Evidence

paraphrase[Introduction, paragraphs 1-4]

“Semaglutide, a GLP-1 receptor mono-agonist, is in phase 3 development for noncirrhotic MASH, having demonstrated histological improvements in a phase 2 MASH trial.”

direct quote[Introduction, paragraph 4]

“The addition of glucagon (GCG) agonist activity to GLP-1 agonism has shown promise for providing greater reduction of hepatic fat, an early marker of improvement in MASH.”